trending Market Intelligence /marketintelligence/en/news-insights/trending/H_bI5dmcSOzeZJJvCe2rzQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Moody's revises outlook on Teva to negative

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Moody's revises outlook on Teva to negative

Moody's affirmed Teva Pharmaceutical Industries Ltd.'s Baa2 issuer rating and changed the ratings outlook to negative from stable.

The outlook change is based on the U.S. District Court for the District of Delaware's rejection of the company's patent infringement claims against the generic versions of its drug Copaxone.

Moody's believes the company will not be able to reduce leverage as there is an increasing risk of a Copaxone generic launch in 2017 after the court ruling.

The Baa2 rating takes into account the company's scale, diversity and its status as the largest generic drug company. The rating agency said the rating is also supported by the company's strong and stable cash flow.

Factors constraining the rating include Teva's high financial leverage after the 2016 Allergan generics acquisition, integration risk of Actavis generics and the company's profit concentration in Copaxone.